EUVIMEDEUVIMED entdecken
Editorial

Will the UK–US pharmaceuticals deal really cause 229,000 excess deaths? A critical appraisal

Sreeram V Ramagopalan, Michael L Ryan

Journal of Comparative Effectiveness Research · 2026-11 · 15 (11)

DOI: 10.57264/cer-2026-0186 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-11. Verfasst von Sreeram V Ramagopalan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pharmaceutical Medicine Research, King's College London, London, SE1 9NH, UK. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

health economicshealth policypharmaceutical pricing

Autor:innen und Institutionen

  • Centre for Pharmaceutical Medicine Research, King's College London, London, SE1 9NH, UK.
  • Koios Enterprises & Consulting, Denver, CO, USA.

Zitieren

APA

Ramagopalan, S. V., & Ryan, M. L. (2026). Will the UK–US pharmaceuticals deal really cause 229,000 excess deaths? A critical appraisal. Journal of Comparative Effectiveness Research, 15(11). https://doi.org/10.57264/cer-2026-0186

Vancouver

Ramagopalan SV, Ryan ML. Will the UK–US pharmaceuticals deal really cause 229,000 excess deaths? A critical appraisal. Journal of Comparative Effectiveness Research. 2026;15(11). doi:10.57264/cer-2026-0186

BibTeX
@article{Ramagopalan2026,
  author = {Ramagopalan, Sreeram V and Ryan, Michael L},
  title = {Will the UK–US pharmaceuticals deal really cause 229,000 excess deaths? A critical appraisal},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.57264/cer-2026-0186}
}
Kostenlos starten →